首页> 外文期刊>Cancer immunology, immunotherapy : >Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures.
【24h】

Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures.

机译:尽管在一部分培养物中调节性CD4 + T细胞增加,但人CD80 / IL2慢病毒转导的急性髓性白血病细胞仍能在体外增强细胞溶解活性。

获取原文
获取原文并翻译 | 示例
       

摘要

Immunotherapeutic strategies are increasingly being explored as a method of enhancing anti-tumour immune responses in patients with acute myeloid leukaemia (AML). Regulatory CD4(+) T cells (Tregs) suppress effector T and natural killer (NK) cells and therefore pose a potential challenge to the efficacy of immunotherapy. AML cells transduced with a lentivirus expressing CD80 (B7.1) and IL2 (LV-CD80/IL2) are capable of stimulating T and NK cell cytotoxicity in vitro. This study examines the effect of CD80/IL2 modified AML cells on Treg number and function. We report a significant increase in the number of CD8(+) T cells (P = 0.046) CD3(-)CD56(+) NK cells (P = 0.028) and CD3(+)CD4(+)CD25(high)Foxp3(+) Tregs (P = 0.043) following stimulation for 7 days with allogeneic LV-CD80/IL2 AMLs. In contrast, autologous LV-CD80/IL2 AML cell cultures provide a weaker stimulation with a lower number of CD8(+) T cells (P = 0.011) and no change in NK cell or Treg numbers. However, an increase in cytotoxic CD8(+) T cells and NK cells are detected following both allogeneic and autologous LV-CD80/IL2 stimulation as demonstrated by an increase in IFN-gamma and CD107a expression. Despite the presence of increased numbers of Tregs with suppressive activity in a subset of cultures, increased lysis of unmodified AMLs was still achieved following allogeneic (day 0, 2.2%; day 7, 20.4%) and more importantly, autologous LV-CD80/IL2 culture in which AML patients had recently received intensive chemotherapy (day 0, 0%; day 7, 16%). Vaccination with LV-CD80/IL2 therefore provides a potential strategy to enhance anti-leukaemia immune responses without a concomitant stimulation of Treg-mediated inhibition of cytotoxic immunological responses.
机译:免疫治疗策略正在越来越多地作为增强急性髓细胞性白血病(AML)患者抗肿瘤免疫反应的方法进行探索。调节性CD4(+)T细胞(Tregs)抑制效应T和自然杀伤(NK)细胞,因此对免疫疗法的功效提出了潜在的挑战。用表达CD80(B7.1)和IL2(LV-CD80 / IL2)的慢病毒转导的AML细胞能够在体外刺激T和NK细胞的细胞毒性。这项研究检查了CD80 / IL2修饰的AML细胞对Treg数量和功能的影响。我们报告CD8(+)T细胞(P = 0.046)CD3(-)CD56(+)NK细胞(P = 0.028)和CD3(+)CD4(+)CD25(high)Foxp3( +)同种异体LV-CD80 / IL2 AML刺激7天后的Treg(P = 0.043)。相反,自体LV-CD80 / IL2 AML细胞培养物提供的刺激较弱,而CD8(+)T细胞的数量较少(P = 0.011),而NK细胞或Treg数量没有变化。但是,同种异体和自体LV-CD80 / IL2刺激后,都检测到细胞毒性CD8(+)T细胞和NK细胞的增加,如IFN-γ和CD107a表达的增加所证实。尽管在部分培养物中存在具有抑制活性的Tregs数量增加,但同种异体(第0天,2.2%;第7天,20.4%),更重要的是自体LV-CD80 / IL2,仍能实现未修饰AML裂解的增加。 AML患者最近接受了强化化疗的培养(第0天,0%;第7天,16%)。因此,用LV-CD80 / IL2进行疫苗接种可提供增强抗白血病免疫应答而不伴随刺激Treg介导的细胞毒性免疫应答抑制作用的潜在策略。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号